Association of Butyrate Supplementation with Cardiovascular Disease:A Narrative Review
Molecular Nutrition & Food Research · 2026-02 · 70 (3)
DOI: 10.1002/mnfr.70374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Nutrition & Food Research, online erschienen am 05.02.2026. Verfasst von Song-Jie Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Butyrates, Cardiovascular Diseases, Dietary Supplements. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Fundamental Research Funds for the Central Universities, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) have long been a significant source of the global disease burden and a leading cause of death and disability. In recent years, the precise microbiome modulation of the gut has made remarkable progress as a new strategy for treating CVDs, especially its production of short‐chain fatty acids, the primary way the gut flora affects the organism. Butyrate, one of the critical metabolites of short‐chain fatty acids, butyrate uniquely restores intestinal barrier function, suppresses systemic inflammation, promotes immune tolerance, and regulates energy metabolism while antagonizing the pro‐atherogenic metabolite trimethylamine‐N‐oxide (TMAO) via the gut–heart axis. Preclinical studies consistently show that butyrate supplementation mitigates heart failure (HF), atherosclerosis, myocardial infarction, hypertrophic cardiomyopathy, hypertension, and cancer‐related cardiac injury, and concurrently ameliorates metabolic syndrome, dyslipidaemia, and hyperglycaemia. However, clinical translation is currently hampered by a lack of large‐scale human randomized controlled trials (RCTs) and an insufficient understanding of human dose‐response relationships. This review synthesizes knowledge on butyrate's cardiovascular actions, details the underlying mechanisms, and highlights critical evidence gaps to inform future translational research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai, Shandong Province, China.
- Institute of Basic Theory of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
- Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
ORCID-Profile: Hongcai Shang
Förderung
- National Natural Science Foundation of China
- The Fundamental Research Funds for the Central Universities
- China Postdoctoral Science Foundation
Zitieren
APA
Han, S. J., Wei, J. L., Xu, Q. Q., Wei, X. H., & Shang, H. (2026). Association of Butyrate Supplementation with Cardiovascular Disease:A Narrative Review. Molecular Nutrition & Food Research, 70(3). https://doi.org/10.1002/mnfr.70374
Vancouver
Han SJ, Wei JL, Xu QQ, Wei XH, Shang H. Association of Butyrate Supplementation with Cardiovascular Disease:A Narrative Review. Molecular Nutrition & Food Research. 2026;70(3). doi:10.1002/mnfr.70374
BibTeX
@article{Han2026,
author = {Han, Song-Jie and Wei, Jian-Lin and Xu, Qian-Qian and Wei, Xiao-Hong and Shang, Hongcai},
title = {Association of Butyrate Supplementation with Cardiovascular Disease:A Narrative Review},
journal = {Molecular Nutrition & Food Research},
year = {2026},
volume = {70},
number = {3},
doi = {10.1002/mnfr.70374}
}
EUVIMED